14 hours ago
Qiagen, Incyte announce collaboration to develop companion diagnostics
QIAGEN (QGEN) and Incyte (INCY) announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms, a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin, which is being developed in myelofibrosis and essential thrombocythemia. Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions.
